Skip to main content
Premium Trial:

Request an Annual Quote

Carol Nacy, Kay Wagoner, Judith Britz, Sau Lan Tang Staats, Sherri Bale, Scott Yarnell, Mike Tramontina, Gov. Chet Culver, Don Rainey, Sean Stone, David Young, William Rastetter, David Broad, Les Cross, Magda Marquet, M. Scott Salka, James Schaeffer, Robe

Premium
At its 5th annual Entrepreneur Dinner, Women in BIO honored Carol Nacy, a founder and the CEO of Sequella, with a “Special Outstanding Achievement Award for Clinical Trials.”
 
Headquartered in Rockville, Md., Sequella is a clinical-stage biopharmaceutical company focused on commercializing treatments for diseases of epidemic potential. Sequella has a new tuberculosis drug, SQ 109, in Phase I human clinical trials in the United States and a new early detection diagnostic, the TB Patch, in international clinical trials.
 
Women In BIO also bestowed four additional “Outstanding Achievement Awards.” Winners were Kay Wagoner, CEO of Icagen, for equity capital raised; Judith Britz, CEO of Cylex, for products developed; Sau Lan Tang Staats, CEO of Phoenix S&T, for revenue growth; and Sherri Bale, CEO of Gene DX, for employment growth.
 
This year’s Women in BIO dinner was held March 27 at the National Press Club in Washington, DC.
 

 
Scott Yarnell has been elected a partner at Hunton & Williams, where he is a member of the litigation and intellectual property team in the law firm’s McLean, Va., office.
 
Yarnell, who joined Hunton & Williams in 2000, provides counsel to clients on a variety of technologies, including biotechnology and pharmaceuticals, conducts due diligence investigations, and renders opinions on patent infringement, validity and freedom to use. Yarnell, a registered patent attorney, appears before the Board of Patent Appeals and Interferences in appeals and contested cases.
 
He graduated cum laude from Drexel University in 1994 and received his law degree from George Washington University Law School in 1997. Mr. Yarnell is admitted to practice in the District of Columbia, Maryland and Virginia, and before the US Patent and Trademark Office.
 

 
Mike Tramontina has been appointed director of the Iowa Department of Economic Development by Gov. Chet Culver. Tramontina had served as interim director of the agency since January.
 
Tramontina previously served as the director of the Iowa Department of Management for two years during the administration of Culver’s predecessor, Tom Vilsack. Before that, Tramontina served four and a half years as executive director of the Iowa Finance Authority where he coordinated the state’s housing policy. He has served in the US Department of Housing and Urban Development as the secretary’s representative for the Great Plains region, as deputy state treasurer, as a research analyst in the Iowa Senate and as a congressional district aide. He also worked in the private sector as an investment banker in public finance.
 
Tramontina is a native of Sioux City and a graduate of the University of Iowa.
 

 
Don Rainey and Sean Stone have each been elected to three-year terms on the board of directors of the Mid-Atlantic Venture Association.
 
Rainey is a general partner with Intersouth Partners, an early-stage venture capital firm with more than $750 million under management and investments in more than 100 companies. Rainey is a former entrepreneur with a track record of a number of successful businesses including Attitude Network, one of the first entertainment networks on the Internet, which was sold to TheGlobe.com in 1999.
 
In addition to serving on numerous regional private company and non-profit boards, Rainey's background in identifying and evaluating life science and information technology investment opportunities is expected to add strength to MAVA's growing life science initiatives and programs. Rainey also serves as co-chair of MAVA's Capital Connection 2007 event.
 
Stone is a senior vice president in the mid-Atlantic office of SVB Financial Group, with more than fifteen years of experience working with both traditional and online financial services companies. Previously he worked at Capital Advisors Group as vice president of business development for the southeast and southwest regions. For the past several years, Stone has served as a member of the Capital Connection Steering Committee and specifically co-chair of the Outreach Committee.
 
MAVA also announced that Michael Murray, managing director of Deutsche Bank, is leaving the association’s board after five years.
 

 
David Young has been named one of six new partners at the Washington, DC, office of Goodwin Procter, in an expansion of its intellectual property practice. Young focuses on intellectual property counseling, litigation, and appellate practice, including patent litigation, and copyright, trademark, trade dress, and counterfeiting counseling and litigation. He has represented businesses in patent litigation involving a wide variety of technology fields, including biotechnology, mechanical and electrical engineering technology, and computer arts.
 
He received a JD from George Mason University School of Law and a BA from Westminster College.
 

 
BIOCOM, the San Diego-based life sciences industry association representing more than 550 member companies in southern California, has announced eight new members of its 2007-2008 board of directors:
  • William Rastetter, venture partner with Venrock Associates, was named life director for the board. Rastetter joined Venrock last year from Biogen Idec, where he most recently served as executive chairman, and had been president and CEO of a predecessor company, Idec Pharmaceuticals, which he joined at its founding. Rastetter is currently chairman of the board of Illumina, a Venrock-invested company, and was a former chair of BIOCOM’s board. He holds an SB in chemistry from the Massachusetts Institute of Technology and a MA and PhD in chemistry from Harvard University.
  • David Broad, vice president and general manager, Oceanside product operations, Genentech, was named one of two industry directors. He joined Genentech with the acquisition of the Oceanside manufacturing facility from Biogen Idec and had been vice president and general manager of Biogen Idec's West Coast Manufacturing Operations since 2000. He holds a bachelor of science and a doctorate in microbiology from the University of London, where he was also a postdoctoral fellow.
  • Les Cross, CEO and president of DJ Orthopedics, was named one of two industry directors. Cross has been the CEO, president and a director of DJ since 2001. He served as the CEO of DonJoy, the predecessor of the company, from June 1999 until November 2001, and has served as president of DJ Orthopedics, the company's wholly owned operating subsidiary. Cross earned a diploma in medical technology from Sydney Technical College and studied business at the University of Cape Town in Cape Town, South Africa.
  • Magda Marquet, co-president and co-CEO of Althea Technologies, has had over twenty years of experience in the biotechnology industry in the United States and Europe. She was formerly executive director of pharmaceutical development at Vical Incorporated. Prior to joining Vical, Marquet held process development positions at Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro, and Transgene. Marquet holds a PhD in biochemical engineering from the University of Toulouse/INSA.
  • M. Scott Salka, CEO of Ambit Biosciences. Prior to joining Ambit in 2001, he served as the president and CEO of two privately held genomics companies, Arcaris and 454 Life Sciences. He also previously co-founded Sequana Therapeutics. Salka received his MBA from Carnegie Mellon University and his BS in finance from San Diego State University.
  • James Schaeffer, executive director, worldwide licensing and external research - West Coast, Merck Research Laboratories. Schaeffer joined Merck Research Laboratories in 1986. During his first 16 years at MRL, he directed research groups focusing primarily on neuroendocrine-related projects. Schaeffer joined the Department of External Scientific Affairs in 2003 with primary responsibility for all neuroscience licensing. Schaeffer moved to San Diego in 2004 to assume the role of Merck's "Science Scout" on the West Coast with the responsibility to identify new opportunities across all therapeutic areas at all stages of development including enabling technologies.
  • Robert S. Sullivan, founding dean of the University of California, San Diego’s Rady School of Management, was named an academic director. Sullivan is an expert on entrepreneurship, knowledge management, operations and venture financing. Prior to his arrival at UCSD, Sullivan served as dean of the University of North Carolina’s Kenan-Flagler Business School. From 1995 to 1997, Sullivan served as director of the University of Texas at Austin's IC2 Institute. Sullivan holds a doctorate in operations management from Pennsylvania State University, a master's degree in production management and quantitative methods from Cornell University, and a bachelor's degree in mathematics from Boston College.
  • David Marino, principal and executive vice president, The Irving Hughes Group, was named a service provider director. Marino is a licensed California real estate broker who has been exclusively representing tenants since 1991, completing over 10 million square feet of real estate, comprised of over 600 transactions. Marino has been an early stage angel investor in over twenty of his clients and related companies and venture capital funds. Prior to 1991, Marino was employed by Trammell Crow.      
Greg Lucier, president and CEO of Invitrogen, continues as the chairman of BIOCOM's board for 2007-2008.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.